SHR-A1403, a novel c-Met antibody-drug conjugate, overcomes AZD9291 resistance in NSCLC cells overexpressing c-Met.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer science"
DOI: 10.1111/cas.14180
Abstract: EGFR tyrosine kinase inhibitors (TKIs) have been used as the first-line treatment of non-small cell lung cancers (NSCLCs) harboring EGFR-activating mutations, while acquired resistance is ubiquitous and needs to be solved urgently. Here, we introduce… read more here.
Keywords: resistant cells; cells overexpressing; overexpressing met; resistance ... See more keywords